[Discussion] telehealth is doing more work than we give it credit for
telehealth is doing more work than we give it credit for. Not a hot take, just something I have not seen said plainly here.
Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.
Asked for the beyond-use date basis and got a real answer with a stability reference attached. Not universal, apparently.
Switched between two compounded preparations and the concentration on the label was different. Redid the arithmetic on paper before drawing anything.
That is everything I have. The rest is opinion and I have tried to keep it out.
best — the order this archive was captured in
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.
the pharmacy and the prescriber are two separate questions
Removed the staff name. Facilities and clinics can be named here; individuals cannot.
Cosigning the beyond-use date question. What it is based on tells you whether anybody has done stability work.
Did they name the facility?
I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.
I would not read the price difference as a quality signal.
This is the distinction the whole board runs on. Everything else follows from it.
do not assume the concentration matches the branded product
Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.
This. Compounded preparations carry no equivalence claim, and treating them as generics is a category error people make constantly.
Paid noticeably more at one clinic than another for what turned out to be the same facility behind both.
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
a 503B has to register and report, so there is a paper trail to ask for
ask what the beyond-use date is based on
the label on a compounded vial is a legal document, read it
The intake asked me three questions and none of them were about my history. That told me everything I needed to know about the model.
What is the beyond-use date and what is it based on?
Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.
That figure is the starting material purity, not the finished preparation potency. Two different tests.
salt forms are the recurring argument and the answer is boring
shortage status changes and the whole arrangement changes with it
Asked for potency testing on the finished preparation. They had it. I had assumed they would not.
compounded is not generic, there is no equivalence claim
Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.
Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.
Adding one thing — ask for the facility name. Most will give it, and the ones that will not have answered you.
Not convinced. You are comparing a compounded concentration with a branded one and assuming they match.
- 1Removed the staff name. Facilities and clinics can be named here;…22 comments in this branch · started by u/quiet_moderator